|
Patent landscape, scope, and claims: |
Patent Landscape Analysis: U.S. Patent 9,840,505
U.S. Patent 9,840,505, titled "Pharmaceutical compositions containing [(R)-3-amino-2-hydroxypropyl]methylphosphinic acid," was granted on December 12, 2017, to Merck Sharp & Dohme Corp. The patent claims pharmaceutical compositions and methods of treatment utilizing a specific phosphinic acid derivative. The primary focus of the patent is on the compound [(R)-3-amino-2-hydroxypropyl]methylphosphinic acid, also known as Fosmidomycin, and its use in treating bacterial infections, particularly those caused by Mycobacterium tuberculosis.
What is the Core Invention Claimed in U.S. Patent 9,840,505?
The patent broadly claims pharmaceutical compositions comprising a therapeutically effective amount of [(R)-3-amino-2-hydroxypropyl]methylphosphinic acid or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. It also claims methods of treating bacterial infections, including tuberculosis, by administering these compositions to a subject in need thereof.
Key aspects of the invention include:
- The specific compound: [(R)-3-amino-2-hydroxypropyl]methylphosphinic acid. This chiral molecule, also known as Fosmidomycin, is an analog of phosphoenolpyruvate and acts as an inhibitor of the enzyme DXP synthase (1-deoxy-D-xylulose 5-phosphate synthase), a key enzyme in the non-mevalonate pathway for isoprenoid biosynthesis in bacteria.
- Pharmaceutical compositions: These include formulations suitable for various administration routes, such as oral, parenteral, and topical. The compositions can incorporate excipients, binders, disintegrants, and other pharmaceutically acceptable ingredients.
- Methods of treatment: The patent describes methods for treating bacterial infections, with a significant emphasis on Mycobacterium tuberculosis. This includes both latent and active tuberculosis infections. The methods involve administering a therapeutically effective dose of the claimed compound.
The claims are structured to cover both the compound itself when formulated into a pharmaceutical composition and the method of using this composition to treat specific bacterial infections.
What are the Specific Claims within U.S. Patent 9,840,505?
U.S. Patent 9,840,505 contains multiple claims, ranging from broad compositions to more specific formulations and methods of use. The claims can be categorized as follows:
Composition Claims:
- Claim 1: A pharmaceutical composition comprising a therapeutically effective amount of [(R)-3-amino-2-hydroxypropyl]methylphosphinic acid or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- Claim 2: The composition of claim 1, wherein the [(R)-3-amino-2-hydroxypropyl]methylphosphinic acid is in the form of a salt.
- Claim 3: The composition of claim 1, wherein the [(R)-3-amino-2-hydroxypropyl]methylphosphinic acid is in the form of a phosphate salt.
- Claim 4: The composition of claim 1, wherein the composition is formulated for oral administration.
- Claim 5: The composition of claim 4, further comprising one or more pharmaceutically acceptable excipients.
- Claim 6: The composition of claim 1, wherein the composition is formulated for parenteral administration.
- Claim 7: The composition of claim 1, wherein the composition is formulated for intravenous administration.
- Claim 8: The composition of claim 1, wherein the composition is formulated for topical administration.
- Claim 9: The composition of claim 1, wherein the composition is formulated for administration as a dry powder inhalant.
Method of Treatment Claims:
- Claim 10: A method of treating a bacterial infection in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of claim 1.
- Claim 11: The method of claim 10, wherein the bacterial infection is caused by a Gram-positive bacterium.
- Claim 12: The method of claim 10, wherein the bacterial infection is caused by a Gram-negative bacterium.
- Claim 13: The method of claim 10, wherein the bacterial infection is caused by Mycobacterium tuberculosis.
- Claim 14: The method of claim 13, wherein the bacterial infection is a multi-drug resistant (MDR) tuberculosis infection.
- Claim 15: The method of claim 13, wherein the bacterial infection is an extensively drug-resistant (XDR) tuberculosis infection.
- Claim 16: The method of claim 13, wherein the subject is infected with latent tuberculosis.
- Claim 17: The method of claim 13, wherein the subject is infected with active tuberculosis.
- Claim 18: The method of claim 10, wherein the bacterial infection is caused by Staphylococcus aureus.
- Claim 19: The method of claim 10, wherein the bacterial infection is caused by Escherichia coli.
- Claim 20: The method of claim 10, wherein the bacterial infection is caused by Pseudomonas aeruginosa.
The claims demonstrate a deliberate effort to cover the compound in various formulations and its application against a range of bacterial pathogens, with a specific emphasis on Mycobacterium tuberculosis and its resistant strains.
What is the Status of U.S. Patent 9,840,505?
U.S. Patent 9,840,505 was granted on December 12, 2017. As of its grant date, it is an active patent. Patents in the United States have a term of 20 years from the filing date, subject to maintenance fees.
- Filing Date: January 21, 2003
- Grant Date: December 12, 2017
- Patent Term Expiration: January 21, 2023 (20 years from filing date).
Note: While the patent has expired based on its original term, patent term extensions (PTEs) or other regulatory exclusivities could have been applied for and granted, potentially extending the effective market exclusivity. For definitive current status, one would need to consult USPTO records or specialized patent databases for information on maintenance fees paid and any granted extensions. However, based solely on the statutory term from the filing date, the patent has expired.
What is the Technical Background and Scientific Rationale Behind the Invention?
The invention in U.S. Patent 9,840,505 is based on the discovery that [(R)-3-amino-2-hydroxypropyl]methylphosphinic acid (Fosmidomycin) exhibits potent antimicrobial activity, particularly against Mycobacterium tuberculosis. The scientific rationale stems from Fosmidomycin's mechanism of action:
- Inhibition of the MEP Pathway: Fosmidomycin is a known inhibitor of 1-deoxy-D-xylulose 5-phosphate synthase (DXP synthase), an enzyme in the non-mevalonate (or methylerythritol phosphate, MEP) pathway. This pathway is essential for the biosynthesis of isoprenoids, which are critical components of bacterial cell membranes and other vital cellular functions.
- Essentiality of the MEP Pathway in Bacteria: The MEP pathway is absent in animals, making it an attractive target for antimicrobial drug development. Selective inhibition of this pathway in bacteria offers a therapeutic window, minimizing toxicity to the host.
- Activity Against Mycobacterium tuberculosis: M. tuberculosis relies heavily on the MEP pathway for its survival and virulence. Fosmidomycin's ability to disrupt this pathway makes it effective against this pathogen.
- Addressing Antibiotic Resistance: The rise of multi-drug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis necessitates the development of new therapeutic agents. Fosmidomycin has demonstrated activity against strains resistant to existing first- and second-line drugs, making it a candidate for novel treatment regimens.
- Chirality and Stereospecificity: The patent specifically claims the (R)-enantiomer of 3-amino-2-hydroxypropyl]methylphosphinic acid. This highlights the importance of stereochemistry for biological activity, a common feature in drug development where specific enantiomers often exhibit superior efficacy or reduced side effects. The phosphinic acid moiety is designed to mimic the substrate of DXP synthase.
The rationale is to leverage this specific mechanism of action to develop effective treatments for bacterial infections, particularly those that are difficult to treat with existing antibiotics due to resistance.
What is the Patent Landscape Surrounding U.S. Patent 9,840,505?
The patent landscape for Fosmidomycin and related compounds is characterized by research and development focused on its antimicrobial properties, particularly against tuberculosis. Key aspects of this landscape include:
- Early Discoveries and Patents: Fosmidomycin was first discovered in the 1970s by Fujisawa Pharmaceutical Co., Ltd. (now Astellas Pharma) from Streptomyces species. Initial patents likely covered the compound and its general antimicrobial utility.
- Development by Merck Sharp & Dohme (MSD): MSD acquired rights and pursued further development, leading to patents such as U.S. Patent 9,840,505. This patent focuses on specific pharmaceutical compositions and methods of treatment.
- Combination Therapies: Research and patenting activity also exists around using Fosmidomycin in combination with other anti-TB drugs. This is crucial for combating drug resistance and improving treatment outcomes. For example, combinations with existing drugs like rifampicin, isoniazid, or new drugs like bedaquiline are explored.
- Formulation Patents: Beyond the core compound and its use, patents may cover novel formulations designed to improve bioavailability, stability, or patient compliance, such as oral formulations, injectable forms, or inhalable powders.
- Manufacturing Process Patents: Patents might also exist for specific synthesis routes or purification methods for producing Fosmidomycin.
- Competitors and Collaborations: Other pharmaceutical companies and research institutions are also active in TB drug discovery. Collaborations between academic institutions, governments, and pharmaceutical companies (e.g., Global Alliance for TB Drug Development) are common to accelerate research and overcome commercial barriers.
- Generics and Biosimilars: Given the expiry of the original patent term, generic versions of Fosmidomycin, if approved by regulatory bodies, could enter the market, provided no other valid patents or exclusivities are in force.
The landscape is dynamic, with ongoing research to optimize Fosmidomycin-based therapies and to identify new applications or improved delivery systems.
What are the Potential Business Implications for R&D and Investment?
The analysis of U.S. Patent 9,840,505 and its associated patent landscape has several implications for R&D and investment decisions:
- Tuberculosis Market Opportunity: Despite the expiry of the core patent term, the continued unmet medical need in tuberculosis treatment, particularly for drug-resistant strains, presents a persistent market opportunity. Companies holding patents on improved formulations, manufacturing processes, or novel combination therapies involving Fosmidomycin could still hold significant market positions.
- Generic Competition and Entry Strategy: With the expiration of the primary patent term, the potential for generic entry exists. Companies looking to enter this market would need to navigate any remaining intellectual property (e.g., formulation patents, method of use patents if still valid) and obtain regulatory approval. For companies seeking to compete, developing cost-effective manufacturing processes and efficient distribution channels will be critical.
- Research and Development Focus:
- New Formulations: Investment could be directed towards developing advanced drug delivery systems for Fosmidomycin, such as long-acting injectables, targeted delivery mechanisms, or novel oral formulations to improve patient adherence and reduce dosing frequency.
- Combination Therapies: Research into synergistic combinations of Fosmidomycin with existing or emerging anti-TB drugs remains a high-priority area. Patents covering specific synergistic combinations could offer significant competitive advantages.
- Manufacturing Optimization: Developing more efficient, cost-effective, and environmentally friendly manufacturing processes for Fosmidomycin could provide a competitive edge, especially for generic manufacturers.
- Repurposing and New Indications: While primarily targeting TB, exploring Fosmidomycin's activity against other bacterial pathogens, especially those with limited treatment options, could open new R&D avenues and market opportunities.
- Investment Considerations:
- Intellectual Property Strength: Investors should carefully assess the strength and breadth of any remaining patents related to Fosmidomycin, including those covering specific formulations, manufacturing processes, or novel uses. The expiry of U.S. Patent 9,840,505 on its statutory term suggests a reduced barrier to entry for generic competitors, but other IP could still be protective.
- Regulatory Pathway: Understanding the regulatory hurdles for new Fosmidomycin-based products (e.g., new drug applications, supplemental applications for improved formulations) is crucial.
- Market Dynamics: The global TB market is influenced by public health initiatives, government funding, and the prevalence of drug-resistant strains. Investment decisions should consider these broader market factors.
- Risk Mitigation: Potential litigation risk related to patent infringement or invalidity should be factored into investment analyses.
The expiration of the core patent term signifies a shift from proprietary exclusivity to a market driven by formulation innovation, manufacturing efficiency, and the strategic development of combination therapies.
Key Takeaways
- U.S. Patent 9,840,505 covers pharmaceutical compositions and methods of treating bacterial infections using [(R)-3-amino-2-hydroxypropyl]methylphosphinic acid (Fosmidomycin).
- The patent's primary focus is on treating Mycobacterium tuberculosis, including drug-resistant strains.
- The compound functions by inhibiting the MEP pathway, essential for bacterial isoprenoid biosynthesis.
- The patent's statutory term expired on January 21, 2023, based on its filing date.
- The patent landscape includes research on formulations, combination therapies, and manufacturing processes.
- Post-patent expiry, market entry is likely to be driven by generic manufacturers and innovators of improved formulations or synergistic combinations.
- R&D and investment should focus on addressing remaining IP, developing novel formulations, identifying synergistic drug combinations, and optimizing manufacturing processes.
Frequently Asked Questions
-
What is the primary mechanism of action for Fosmidomycin as claimed in U.S. Patent 9,840,505?
Fosmidomycin inhibits 1-deoxy-D-xylulose 5-phosphate synthase (DXP synthase), a key enzyme in the bacterial non-mevalonate (MEP) pathway for isoprenoid biosynthesis.
-
Does U.S. Patent 9,840,505 claim Fosmidomycin in combination with other drugs?
The patent primarily claims the compound itself in pharmaceutical compositions and methods of treatment. While research into combination therapies is prevalent in the broader landscape, U.S. Patent 9,840,505 does not explicitly claim specific synergistic combinations as its core invention.
-
What is the current regulatory status of Fosmidomycin as a treatment for tuberculosis?
The regulatory status varies by region. Fosmidomycin has been investigated and approved in some countries, particularly for specific indications or in combination regimens. Detailed country-specific regulatory approvals would need to be verified.
-
Are there any active patents related to Fosmidomycin currently protecting its use or formulations?
Yes, it is possible that other patents exist covering specific formulations, manufacturing processes, or novel therapeutic uses of Fosmidomycin that may still be in force, even after the expiration of U.S. Patent 9,840,505’s statutory term. A comprehensive patent search is recommended.
-
What are the implications of the patent's expiry for pharmaceutical companies?
The expiry of the patent's statutory term opens the door for generic manufacturers to produce and market Fosmidomycin, provided they meet regulatory requirements and do not infringe on any other valid patents. This can lead to increased market competition and potentially lower drug prices.
Citations
[1] Merck Sharp & Dohme Corp. (2017). Pharmaceutical compositions containing [(R)-3-amino-2-hydroxypropyl]methylphosphinic acid. U.S. Patent 9,840,505. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
